Kezar Life Sciences Inc expected to post a loss of 38 cents a share - Earnings Preview

Kezar Life Sciences

08/03/2024 11:13

* Kezar Life Sciences Inc  KZR.OQ   KZR.O  is expected
to show no
change in quarterly revenue when it reports  results on March 12
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Kezar Life Sciences Inc
is for
a loss of 38 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $13.00​, above​ its last closing price of $1.00.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.36       -0.35      -0.32     Beat    8.4
 Jun. 30 2023  -0.32       -0.32      -0.34     Missed  -6.2
 Mar. 31 2023  -0.29       -0.29      -0.31     Missed  -7.5​
 Dec. 31 2022              -0.28      -0.25     Beat    9.6
 ​​Sep.        -0.27       -0.27      -0.25     Beat    7.5
 30 2022                                                
 Jun. 30 2022  -0.27       -0.27      -0.25     Beat    9​
 Mar. 31 2022  -0.28       -0.28      -0.26     Beat    8
 Dec. 31 2021  -0.33       -0.30      -0.25     Beat    15.7
 This summary was machine generated March 8 at 11:13 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)